Counteracting Age-related Loss of Skeletal Muscle Mass (CALM)

Summary

Up to 66 healthy elderly individuals (at least 65 years old) are recruited as subjects. They will be recruited as a subgroup to protocol ID: H-4-2013-070.

Upon inclusion, each individual will be randomized into one of the five groups stratified according to gender (M/F) and 30s chair stand (\<16 OR ≥16). The five groups are: Heavy Resistance Training (N=12), Light Intensity Training (N=12), Protein Whey (N=15), Protein Collagen (N=15) and Carbohydrate (N=12). The individuals randomized into one of the supplementation groups (Protein Whey, Protein Collagen or Carbohydrate) will be blinded to the supplement content.

Assessments will be performed at Baseline (before intervention start) and after 12 months of intervention.

The primary outcomes are measures of muscle protein synthesis rate measured as the fractional synthesis rate from Baseline to 12 months of intervention.

The hypotheses are i) that basal and protein-stimulated muscle protein synthesis rates are elevated in the exercise training groups after 12 months of intervention. ii) prolonged intake of protein of different quality will improve the muscle protein synthetic response to protein intake after 12 months of intervention.

Conditions

• Sarcopenia
• Muscle Loss

Interventions

PROCEDURE

Heavy Resistance Training

Supervised Heavy Resistance Training three times weekly for 52 weeks.

PROCEDURE

Light Intensity Training

Home-based Light Intensity Training three-five times weekly for 52 weeks.

DIETARY_SUPPLEMENT

Protein Whey

Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.

DIETARY_SUPPLEMENT

Protein Collagen

Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.

DIETARY_SUPPLEMENT

Carbohydrate

Two daily 30 g carbohydrate supplementations for 52 weeks.

Sponsors & Collaborators

• University of Copenhagen

  collaborator OTHER

• Arla Foods

  collaborator INDUSTRY

• Bispebjerg Hospital

  lead OTHER

Principal Investigators

• Rasmus L. Bechshoeft, MD · Bispebjerg Hospital

• Lars Holm, assoc. prof. · Bispebjerg Hospital

• Michael Kjaer, MD, prof. · Bispebjerg Hospital

• Søren Reitelseder, PhD · Bispebjerg Hospital

• Jacob Bülow, MD PhD stud · Bispebjerg Hospital

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

65 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2014-04-01

Primary Completion

2019-06-30

Completion

2019-08-31

Countries

• Denmark